Nanomedicine in Cancer Clinics: Are We There Yet?

Despite preclinical success of nanomedicine for anticancer activity, the clinical success of the same has been very limited. This review evaluates and discusses the therapeutic potential and pitfalls of clinically undergoing and successful nanoformulations in treatment of globally prevalent cancers. Cancer is the second leading cause of disease-related deaths all over the world. Alongside the FDA approved indication, chemotherapeutic nanoformulations like Abraxane and Doxil are alternatively evaluated in other cancers providing positive results. The review gives an update on the nanoformulations, which are currently in phase I and phase II clinical trials and approved for the treatment of prevalent cancers. Emphasis on the immediate need for reforming the guidelines for nanoformulations allows significant advances in the field of cancer nano-therapy in the near future.